Author

Maria Sanchez-Azofra

CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

Maria Sanchez-Azofra  et al.

CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION
SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION

Maria Sanchez-Azofra  et al.

ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE
ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE

Maria Sanchez-Azofra  et al.

CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE
CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE

Maria Sanchez-Azofra  et al.

ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE
ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE

Maria Sanchez-Azofra  et al.

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE

Maria Sanchez-Azofra  et al.

ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE
ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE

Maria Sanchez-Azofra  et al.

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Maria Sanchez-Azofra  et al.

INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE
INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE

Maria Sanchez-Azofra  et al.

CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE
CORRELATION BETWEEN ULTRASOUND AND ENDOSCOPIC SCORES FOR ASSESSING INFLAMMATORY ACTIVITY IN CROHN'S DISEASE

Maria Sanchez-Azofra  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Maria Sanchez-Azofra  et al.

Item 1 - 12 / 12
1